Evolution of Cancer Care in Response to the COVID-19 Pandemic

Eric A Coomes; Humaid O Al-Shamsi; Brandon M Meyers; Waleed Alhazzani; Ahmad Alhuraiji; Roy F Chemaly; Meshari Almuhanna; Robert A Wolff; Nuhad K Ibrahim; Melvin L K Chua; Sebastien J Hotte; Tarek Elfiki; Giuseppe Curigliano; Cathy Eng; Axel Grothey; Conghua Xie

doi:10.1634/theoncologist.2020-0451

Evolution of Cancer Care in Response to the COVID-19 Pandemic

Oncologist. 2020 Sep;25(9):e1426-e1427. doi: 10.1634/theoncologist.2020-0451. Epub 2020 Jul 7.

Authors

Eric A Coomes¹, Humaid O Al-Shamsi², Brandon M Meyers³, Waleed Alhazzani⁴, Ahmad Alhuraiji⁵, Roy F Chemaly⁶, Meshari Almuhanna⁷, Robert A Wolff⁸, Nuhad K Ibrahim⁹, Melvin L K Chua¹⁰, Sebastien J Hotte³, Tarek Elfiki¹¹, Giuseppe Curigliano¹², Cathy Eng¹³, Axel Grothey¹⁴, Conghua Xie¹⁵

Affiliations

¹ Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Canada.
² Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates; Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Emirates Oncology Society, Dubai, United Arab Emirates.
³ Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Canada.
⁴ Department of Health Research Methods, Evidence, and Impact and Department of Medicine, McMaster University, Hamilton, Canada.
⁵ Department of Hematology, Kuwait Cancer Control Center, Kuwait City, Kuwait.
⁶ Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁷ Min-Sheng General Hospital, Taoyuan District, Taoyuan City, Taiwan.
⁸ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
¹⁰ Divisions of Radiation Oncology and Medical Sciences, National Cancer Center Singapore, Singapore; Oncology Academic Program, Duke-National University of Singapore Medical School, Singapore; Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
¹¹ Windsor Regional Cancer Center, Windsor, Canada; Department of Oncology, Schulich School of Medicine, University of Western Ontario, London, Canada.
¹² Department of Oncology and Hemato-Oncology and Division of Early Drug Development for Innovative Therapy, University of Milan, Milan, Italy; European Institute of Oncology, IRCCS, and University of Milano, Milan, Italy.
¹³ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
¹⁴ West Cancer Center, University of Tennessee, Memphis, Tennessee, USA.
¹⁵ Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.

Abstract

In this study, whole exome sequencing was conducted on tumor samples and paired germline samples from patients with Sertoli‐Leydig cell tumors to explore not only DICER1 mutations for Chinese populations but also other genetic variations related to pathogenesis and prognosis, which could lay a preliminary foundation for genetic counseling.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Neoplasms* / epidemiology
Neoplasms* / therapy
Pandemics
SARS-CoV-2